dasatinib (Sprycel)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Sprycel

Indications

Dosage

usual dose is 70 mg PO BID

Tabs: 20, 50, 70, 80, 100, 140 mg[5]

Pharmacokinetics

Adverse effects

Drug interactions

Mechanism of action

More general terms

References

  1. Prescriber's Letter 13(8): 2006 FDA Approves Sprycel, a New Treatment for a Rare Type of Leukemia Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220812&pb=PRL (subscription needed) http://www.prescribersletter.com
  2. Cortes JE et al Results of dasatinib therapy in patients with early chronic- phase chronic myeloid leukemia. J Clin Oncol 2010 Jan 20; 28:398. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20008620
  3. 3.0 3.1 FDA MedWatch: 10/11/2011 Sprycel (dasatinib): Drug Safety Communication - Risk of Pulmonary Arterial Hypertension http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm275176.htm
  4. 4.0 4.1 4.2 4.3 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
  5. 5.0 5.1 dasatinib (Rx) Medscape https://reference.medscape.com/drug/sprycel-dasatinib-342199

Database